MAIA Biotechnology, Inc. (MAIA) has successfully raised $33 million to fund its pivotal Phase 3 trial of Ateganosine (THIO), a promising telomere-targeting therapy for non-small cell lung cancer (NSCLC). This capital infusion ensures that MAIA can proceed with the THIO-104 trial, which aims to evaluate the efficacy of Ateganosine in combination with checkpoint inhibitors for patients who have exhausted standard treatment options.

The significance of this trial lies in its potential to redefine treatment protocols for NSCLC, a leading cause of cancer mortality. If successful, Ateganosine could become the first telomere-targeting therapy, offering new hope for patients with limited options. The trial will compare the combination of Ateganosine and checkpoint inhibitors against standard chemotherapy, with overall survival as the primary endpoint.

For investors, MAIA’s stock, which has fluctuated between $1.23 and $3.19 over the past year, closed at $1.24, reflecting a 3.33% increase. However, it dipped to $1.20 in after-hours trading, highlighting the volatility surrounding clinical trial outcomes and funding developments.

Source: nasdaq.com